'On consolidated basis

Quarter ended March 2025 compared with Quarter ended March 2024.

Net sales (including other operating income) of Sun Pharmaceutical Industries has increased 8.14% to Rs 12958.84 crore.  Operating profit margin has jumped from 25.33% to 28.68%, leading to 22.44% rise in operating profit to Rs 3,716.09 crore.  Raw material cost as a % of total sales (net of stock adjustments) increased from 13.67% to 13.97%.   Purchase of finished goods cost fell from 8.02% to 7.85%.   Employee cost increased from 18.75% to 18.85%.   Other expenses fell from 34.81% to 31.18%.   Loss on forex transaction rose from 0.46% to 2.21%.   

Other income rose 1.14% to Rs 612.87 crore.  PBIDT rose 18.89% to Rs 4328.96 crore.  Provision for interest fell 33.21% to Rs 49.14 crore.  Loan funds declined from Rs 3,273.67 crore as of 31 March 2024 to Rs 2,362.19 crore...

• 

  (30-May-2025)

  Shivalik Bimetal Controls

  Net down 18% hit by lower OI, lower share of profit from associates and higher taxation
• 

  (30-May-2025)

  Fluidomat

  Net up 54% on good operating show
• 

  (30-May-2025)

  Senco Gold

  OP surged 44.79%
• 

  (30-May-2025)

  Mazagon Dock Shipbuilders

  Net down 51% as OPM crashes by 1400 bps